Cipla
Cipla Share Price: After company reports healthy March quarter numbers, brokerages turn bullish on stock; recommend buy
Wed, May 11, 2022
Cipla Share Price:Brokerages are bullish on the Cipla shares and expects a 28 per cent upside in this stock. A healthy March quarter results will likely act as a trigger for the upside, they opined.
More >
Q4 Results 2022: Cipla, Max Financial Services, Torrent Power, Ajanta Pharma, Welspun India declare March quarter results; see key highlights
Tue, May 10, 2022
Cipla Q4 results 2022: Drug major Cipla on Tuesday said its consolidated profit after tax declined by 12 per cent to Rs 362 crore for the fourth quarter ended March 2022
More >
Cipla Q4 results 2022 Preview: March quarter results on Tuesday; here is what to expect from company earnings, stock
Mon, May 09, 2022
Pharma major Cipla's will announce its fourth-quarter results on Tuesday. Senior Research Analyst at Zee Business Kushal Gupta's brings his earnings estimates in this report.
More >
Pharma Stocks in Focus: Alkem Lab & IPCA Lab among 4 stocks that may benefit most from 10.8% hike in drugs from April 1
Thu, Mar 31, 2022
The National Pharma Pricing Authority (NPPA) has approved 10.8% hike in over 800 essential drugs starting April 1,2022. This is the biggest hike by NPPA in the last 10 years.
More >
DGGI acts on pharma companies for GST evasion; Dr Reddy's, Glenmark, Aurobindo Pharma, Mylan and Cipla come under hammer
Wed, Mar 30, 2022
Directorate General of GST Intelligence (DGGI) which works under the aegis of the Ministry of Finance has taken action against many big pharma companies in the country for not filing Goods and Services Tax (GST). The pharma giants included are Dr. Reddys Laboratories, Glenmark, Aurobindo Pharma, Mylan and Cipla, as reported by Zee Business’s Tarun Sharma.
More >
Value Pick: Strong India franchise, rich product pipeline makes Cipla shares lucrative; brokerages see 15% upside
Mon, Mar 14, 2022
Several brokerages are betting big on Cipla Limited stocks on the back of robust fundamentals, strong product pipeline in US and improved business outlook. They see an upside of up to 15 per cent in the stock price and find the current valuations attractive.
More >
Cipla Q3FY22 Preview: Pharma major likely to report muted earnings, profit may slip up to 12% YoY
Mon, Jan 24, 2022
The pharmaceutical major Cipla is likely to report muted third quarter earnings for the financial year 2021-22, most of the brokerage houses and analysts predict in their results preview.
More >
Global View: ICICI Bank, Bandhan Bank, Cipla and Container Corp could give 15-40% return in long term
Mon, Jan 24, 2022
The Indian markets are likely to witness some volatility on Monday tracking weak global cues, but there will be stock-specific action in which global brokerage came out with their reports on business development, or earnings outlook.
More >
Cipla receives USFDA nod to market Lanreotide injection in American market
Sun, Dec 19, 2021
Drug major Cipla on Sunday said it has received approval from the US health regulator to market the Lanreotide injection, used for the treatment of acromegaly and gastroenteropancreatic neuroendocrine tumors, in the American market
More >
Freaky Friday: Markets witness freefall - These stocks led the plunge but pharma scrips shone
Fri, Nov 26, 2021
As the bears grip the market during Friday’s session, metal, auto, and pharma stocks witnessed a maximum buzz. In this regard, JSW Steel, Tata Motors, Hindalco slipped most, while Cipla and Dr Reddy’s were the top gainers in the otherwise negative market.
More >
